A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer

BACKGROUND: Lenvatinib is a multikinase inhibitor approved to treat radioiodine-refractory differentiated thyroid cancer (RR-DTC) at a starting dose of 24 mg/day. This study explored, in a double-blinded fashion, whether a starting dose of 18 mg/day would provide comparable efficacy with reduced tox...

Descripción completa

Detalles Bibliográficos
Autores principales: Brose, Marcia S, Panaseykin, Yury, Konda, Bhavana, de la Fouchardiere, Christelle, Hughes, Brett G M, Gianoukakis, Andrew G, Joo Park, Young, Romanov, Ilia, Krzyzanowska, Monika K, Leboulleux, Sophie, Binder, Terri A, Dutcus, Corina, Xie, Ran, Taylor, Matthew H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852210/
https://www.ncbi.nlm.nih.gov/pubmed/34664662
http://dx.doi.org/10.1210/clinem/dgab731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852210/
https://www.ncbi.nlm.nih.gov/pubmed/34664662
http://dx.doi.org/10.1210/clinem/dgab731

Ejemplares similares